AGEN
Price:
$2.72
Market Cap:
$63.81M
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 m...[Read more]
Industry
Biotechnology
IPO Date
2000-02-08
Stock Exchange
NASDAQ
Ticker
AGEN
According to Agenus Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 74.19M. This represents a change of -81.28% compared to the average of 396.23M of the last 4 quarters.
The mean historical Enterprise Value of Agenus Inc. over the last ten years is 395.45M. The current 74.19M Enterprise Value has changed 1.78% with respect to the historical average. Over the past ten years (40 quarters), AGEN's Enterprise Value was at its highest in in the June 2021 quarter at 1.21B. The Enterprise Value was at its lowest in in the September 2024 quarter at 128.47M.
Average
395.45M
Median
418.33M
Minimum
203.02M
Maximum
575.94M
Discovering the peaks and valleys of Agenus Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 237.84%
Maximum Annual Enterprise Value = 575.94M
Minimum Annual Increase = -48.22%
Minimum Annual Enterprise Value = 203.02M
Year | Enterprise Value | Change |
---|---|---|
2023 | 298.23M | -48.22% |
2022 | 575.94M | 14.39% |
2021 | 503.48M | -0.19% |
2020 | 504.42M | -1.28% |
2019 | 510.96M | 128.17% |
2018 | 223.94M | -47.14% |
2017 | 423.67M | 2.59% |
2016 | 412.98M | 38.64% |
2015 | 297.89M | 46.73% |
2014 | 203.02M | 237.84% |
The current Enterprise Value of Agenus Inc. (AGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
459.22M
5-year avg
478.61M
10-year avg
395.45M
Agenus Inc.’s Enterprise Value is less than Icosavax, Inc. (713.87M), greater than Galera Therapeutics, Inc. (-6763403.00), greater than Marker Therapeutics, Inc. (21.61M), less than Edgewise Therapeutics, Inc. (2.77B), greater than Adaptimmune Therapeutics plc (56.86M), less than Mereo BioPharma Group plc (519.43M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), greater than PDS Biotechnology Corporation (36.64M), greater than Leap Therapeutics, Inc. (46.94M), less than Viking Therapeutics, Inc. (4.66B), less than TG Therapeutics, Inc. (5.07B), less than X4 Pharmaceuticals, Inc. (82.50M), less than Madrigal Pharmaceuticals, Inc. (6.70B), less than TCR2 Therapeutics Inc. (79.12M), greater than Affimed N.V. (23.36M), less than ADC Therapeutics SA (252.55M),
Company | Enterprise Value | Market cap |
---|---|---|
713.87M | $769.04M | |
-6763403.00 | $1.69M | |
21.61M | $30.61M | |
2.77B | $2.81B | |
56.86M | $148.98M | |
519.43M | $598.82M | |
-1407736.00 | $17.96M | |
36.64M | $61.73M | |
46.94M | $109.38M | |
4.66B | $4.71B | |
5.07B | $5.01B | |
82.50M | $101.71M | |
6.70B | $6.81B | |
79.12M | $58.11M | |
23.36M | $18.58M | |
252.55M | $195.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agenus Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Agenus Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Agenus Inc.'s Enterprise Value?
What is the highest Enterprise Value for Agenus Inc. (AGEN)?
What is the 3-year average Enterprise Value for Agenus Inc. (AGEN)?
What is the 5-year average Enterprise Value for Agenus Inc. (AGEN)?
How does the current Enterprise Value for Agenus Inc. (AGEN) compare to its historical average?